PF-03715455

PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM) . PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) [1][2].

Product Specifications

CAS Number

[1056164-52-3]

UNSPSC

12352005

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pf-03715455.html

Purity

98.44

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC(C)(C1=NN(C2=CC=C(O)C(Cl)=C2)C(NC(NCC3=CC=CC=C3SC4=CN5C(C6=CC=CC=C6SCCO)=NN=C5C=C4)=O)=C1)C

Molecular Formula

C35H34ClN7O3S2

Molecular Weight

700.27

References & Citations

[1]Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24 (3) :383-92.|[2]Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54 (22) :7797-814.